Monoamine oxidase inhibitors, commonly called MAOIs, are a class of drugs that block the enzyme monoamine oxidase, which normally breaks down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. They were the first modern antidepressants ever developed, introduced in the 1950s, yet today they sit on the back shelf of psychiatry, classified as third-line treatments and prescribed far less often than newer drugs. That gap between their historical significance and their current underuse tells a complicated story about real safety concerns, outdated fears, and a drug class that still has something to offer patients who haven’t responded to anything else.
An Accidental Discovery
The origin of MAOIs is one of medicine’s better serendipity stories. In the early 1950s, doctors treating tuberculosis patients with a drug called iproniazid noticed something unexpected: patients who had been depressed started feeling markedly better, sometimes even euphoric. The drug had been developed as a variation on isoniazid, a standard tuberculosis treatment, and nobody was looking for an antidepressant.1PubMed. The discovery of antidepressants: a winding path Researchers eventually traced the mood-lifting effect to iproniazid’s ability to inhibit monoamine oxidase, which meant neurotransmitters hung around longer in the brain instead of being broken down. Iproniazid became the first drug specifically used as an antidepressant, alongside imipramine, a tricyclic antidepressant discovered around the same time.2PubMed. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today
Iproniazid was eventually pulled from the market due to liver toxicity, but the concept stuck. Over the following decades, pharmaceutical companies developed other MAOIs, including phenelzine (Nardil), tranylcypromine (Parnate), and isocarboxazid (Marplan). These drugs became a mainstay of depression treatment through the 1960s and 1970s, before the arrival of SSRIs like Prozac in the late 1980s pushed them to the margins.
What Monoamine Oxidase Actually Does
Monoamine oxidase is an enzyme that lives on the outer membrane of mitochondria inside cells. Its job is to chemically deactivate monoamine neurotransmitters, including serotonin, norepinephrine, dopamine, and several trace amines like beta-phenylethylamine.3PubMed Central. Monoamine oxidase inactivation: from pathophysiology to therapeutics It does this through a process called oxidative deamination, essentially stripping an amine group off the neurotransmitter molecule and rendering it inactive.
The enzyme comes in two forms, MAO-A and MAO-B. They share about 70% of the same amino acid sequence and look structurally similar at the molecular level, but their active sites differ in important ways.4PubMed Central. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B MAO-A has a single open cavity where molecules bind, while MAO-B has a two-chambered structure with a kind of molecular gate between the compartments.5PubMed. Structural properties of human monoamine oxidases A and B These structural differences determine which neurotransmitters each form prefers. MAO-A is the primary enzyme for breaking down serotonin and norepinephrine in the brain. MAO-B prefers beta-phenylethylamine and, in certain brain regions, takes on a larger share of dopamine breakdown. A single amino acid difference at a key position in the binding site largely determines which form grabs which molecule.6PubMed. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid
This distinction between MAO-A and MAO-B matters enormously for drug design. Block MAO-A and you boost serotonin and norepinephrine, which is what you want for treating depression. Block MAO-B and you preserve dopamine, which is useful for Parkinson’s disease. Block both and you get a broad but less selective effect.
The Different Types of MAOIs
Not all MAOIs work the same way, and lumping them together is one reason the class has a worse reputation than it deserves. The older drugs like phenelzine and tranylcypromine are irreversible and non-selective, meaning they permanently disable both MAO-A and MAO-B. Your body has to build entirely new enzyme molecules before normal neurotransmitter breakdown resumes, a process that can take about two weeks after stopping the drug. This is why washout periods between MAOIs and other medications are typically recommended at one to two weeks.7PubMed. Rapid Monoamine Oxidase Inhibitor Switches in Treatment-Resistant Depression: Safety Evaluation in 3 Cases
Reversible inhibitors of MAO-A, known as RIMAs, represent a newer approach. Moclobemide is the best-known example. It binds to MAO-A but can be displaced by a competing molecule, so its effects wear off within hours rather than weeks. Moclobemide raises serotonin levels most prominently, reaching about 80% inhibition of MAO-A within two hours, with the effect lasting roughly eight to ten hours.8PubMed Central. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. Because the inhibition is reversible, RIMAs carry a substantially lower risk of the dangerous food interactions that made older MAOIs infamous.
Then there are selective MAO-B inhibitors like selegiline and rasagiline, used primarily in Parkinson’s disease. At low doses, these drugs selectively block MAO-B without much effect on MAO-A, preserving dopamine in the parts of the brain where Parkinson’s patients need it most. Rasagiline, for instance, increases dopamine levels in the striatum, the brain region most affected by Parkinson’s, and may have additional protective effects on neurons beyond simple enzyme inhibition.9PubMed Central. Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
The Tyramine Problem
If you’ve heard one thing about MAOIs, it’s probably the “cheese effect.” This is the reason most people think MAOIs are dangerous, and it’s a real concern, though one that’s frequently exaggerated and sometimes avoidable depending on which MAOI you’re taking.
Tyramine is a compound found naturally in aged and fermented foods: aged cheeses, cured meats, sauerkraut, soy sauce, certain wines, and draft beers, among others. Normally, when you eat tyramine-containing foods, MAO-A in your gut and liver breaks the tyramine down before it can cause problems. But when MAO-A is blocked by an irreversible MAOI, tyramine floods through into the bloodstream, where it triggers a massive release of norepinephrine. With as little as 8 to 10 milligrams of tyramine ingested, blood pressure can spike to dangerous levels, a crisis that, untreated, can cause stroke or death.10PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
This is a genuine risk, but the practical burden of dietary restriction has been overstated in some quarters. Modern food production has reduced tyramine levels in many common foods compared with the 1960s, when the original crises were reported. Freshly prepared meals from most cuisines are generally safe. The real culprits are heavily aged or fermented products. Patients on irreversible MAOIs typically receive a list of foods to avoid, and with reasonable attention, hypertensive crises are uncommon.
Serotonin Syndrome and Drug Interactions
The other major safety issue with MAOIs is serotonin syndrome, a potentially life-threatening condition caused by too much serotonin activity in the brain. Symptoms range from mild (agitation, tremor, diarrhea) to severe (high fever, seizures, muscle rigidity). The most dangerous scenario is combining an MAOI, particularly one that inhibits MAO-A, with another serotonergic drug such as an SSRI, SNRI, or the pain medication meperidine (Demerol). This combination can trigger the most severe form of serotonin syndrome and has caused deaths.11PubMed Central. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
The list of drugs that interact badly with MAOIs is long and includes some over-the-counter cold medications containing dextromethorphan or pseudoephedrine, the herbal supplement St. John’s Wort, certain opioid painkillers, and stimulants. This is why prescribers are cautious about MAOIs: one wrong combination can be catastrophic. Patients need to carry a card or wear a medical alert bracelet, and every doctor or pharmacist they encounter needs to know they’re on an MAOI.
Beyond these acute dangers, the everyday side effects of irreversible MAOIs include low blood pressure (particularly on standing), weight gain, sexual dysfunction, insomnia, and muscle twitching.12PubMed Central. Monoamine oxidase inhibitors: clinical review These are manageable for many patients but add to the general reluctance doctors feel when considering the prescription.
Why MAOIs Still Matter for Depression
Despite all these complications, MAOIs have never been shown to be less effective than other antidepressants. A systematic review and network meta-analysis comparing MAOIs with other antidepressant classes for depressive episodes found them similar in efficacy to other treatments.13Acta Psychiatrica Scandinavica. Efficacy and tolerability of monoamine oxidase inhibitors for the treatment of depressive episodes in mood disorders: A systematic review and network meta-analysis The problem is that MAOIs are considered third-line treatments and are underused, particularly in the patients who might benefit most: those with treatment-resistant or atypical depression.
Atypical depression, characterized by mood reactivity (your mood brightens in response to positive events), increased sleep, heavy feelings in the limbs, and sensitivity to rejection, has long been thought to respond particularly well to MAOIs. Research on genetic variations in the MAO-A gene has even found links between certain gene variants and atypical depression in women, with the relationship appearing to be mediated through dopamine levels in spinal fluid.14PubMed. Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression This hints that some individuals may have a neurobiological profile that responds better to MAO inhibition than to other mechanisms.
Social Anxiety and Other Uses
Depression is the most discussed indication, but MAOIs have a strong track record in social anxiety disorder. Six double-blind, placebo-controlled trials have demonstrated that phenelzine is highly effective for social anxiety, producing both symptom relief and improved daily functioning.15International Journal of Neuropsychopharmacology. The evidence-based pharmacotherapy of social anxiety disorder In case series of patients who had failed other treatments, phenelzine produced responses in the majority, with some experiencing dramatic improvements that allowed them to return to school or work.16PubMed. Phenelzine efficacy in refractory social anxiety disorder: a case series
For people living with severe social anxiety that hasn’t responded to SSRIs or therapy, phenelzine represents a genuinely powerful option. Yet many psychiatrists have never prescribed it, partly because they trained after MAOIs fell out of fashion and partly because the dietary and drug-interaction requirements seem daunting to manage.
The Transdermal Patch
One innovation that partially solves the tyramine problem is the selegiline transdermal system, sold as Emsam. Selegiline is a selective MAO-B inhibitor when taken orally at low doses, but when delivered through the skin, it reaches the brain at higher concentrations while largely bypassing the gut. At the lowest effective dose for depression (6 mg over 24 hours), the patch inhibits enough brain MAO to treat depression without significantly blocking MAO-A in the intestinal wall.17PubMed Central. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder This means patients can eat normally without a restricted diet.
Studies in healthy volunteers confirmed a wide tyramine safety margin at this dose, supporting the claim that dietary restrictions are unnecessary.18PubMed. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects At higher patch doses (9 mg or 12 mg per 24 hours), dietary caution returns, because more MAO-A in the gut gets inhibited. But the 6 mg patch offers something close to a free lunch: MAOI-level antidepressant effect without the cheese restrictions.
Switching Between MAOIs
Current guidelines recommend a washout period of one to two weeks when switching from one MAOI to another, to reduce the risk of serotonin toxicity or a hypertensive crisis. In practice, though, the evidence behind that waiting period is thin. A recent case series documented three patients who were rapidly switched between different MAOIs without any washout, and none developed serotonin toxicity or hypertensive problems.19PubMed. Rapid Monoamine Oxidase Inhibitor Switches in Treatment-Resistant Depression: Safety Evaluation in 3 Cases Three cases is hardly definitive, but it adds to earlier reports suggesting that the washout rules may be more conservative than necessary, at least for MAOI-to-MAOI switches (as opposed to switching between an MAOI and a serotonergic drug, which remains genuinely dangerous).
This is a space where clinical practice is slowly catching up to what experienced prescribers have suspected for years. For patients with treatment-resistant depression who need to switch MAOI types, a lengthy washout can mean weeks of unmedicated suffering. If faster switches prove safe in larger studies, it would make MAOIs more practical to use.
Natural MAO Inhibitors in Ayahuasca
The pharmaceutical industry doesn’t have a monopoly on MAO inhibition. Ayahuasca, a ceremonial brew used for centuries in South American indigenous traditions, contains natural MAO-A inhibitors. The key active ingredients are harmala alkaloids, particularly harmine and harmaline, which reversibly inhibit MAO-A.20PubMed. Pharmacokinetics of Hoasca alkaloids in healthy humans Their role in the brew is primarily to protect DMT (dimethyltryptamine), a psychedelic compound that would normally be destroyed by MAO in the gut before it could reach the brain. By blocking MAO-A, the harmala alkaloids allow DMT to survive oral ingestion and produce its hallucinogenic effects.21PubMed. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca
This carries the same safety implications as pharmaceutical MAO inhibition. People who drink ayahuasca are temporarily MAO-A-inhibited, making them vulnerable to the same tyramine reactions and serotonergic interactions as someone on phenelzine. Ceremonial traditions often incorporate dietary restrictions in the days before and after a ceremony, a practice that aligns with the pharmacology even if it wasn’t originally understood in those terms. Anyone taking SSRIs or other serotonergic medications who participates in an ayahuasca ceremony faces a real risk of serotonin syndrome.
Genetic Variation in the MAO-A Gene
People naturally vary in how much MAO-A activity their brains produce, based on a well-studied genetic variation in the promoter region of the MAO-A gene called MAOA-uVNTR. Some variants produce more enzyme (high-activity alleles) and some produce less (low-activity alleles). This variation has been linked to differences in anxiety and behavior, but the relationship is not straightforward: in one study of adolescents, girls with the high-activity allele reported more generalized anxiety, while boys with the low-activity allele had higher social phobia scores.22PubMed. Association study of monoamine oxidase-A gene promoter polymorphism (MAOA-uVNTR) with self-reported anxiety and other psychopathological symptoms in a community sample of early adolescents
The low-activity version of this gene attracted widespread media attention in the 2000s when it was nicknamed the “warrior gene” and linked to aggression and antisocial behavior. That framing was always an oversimplification. The gene interacts with environmental factors, sex hormones, and other genetic variants in ways that make any single behavioral prediction unreliable. What the research does suggest is that baseline MAO-A activity varies meaningfully between individuals, which could in principle help explain why some people respond well to MAOIs and others don’t, though pharmacogenomic testing for MAOI response is not yet standard practice.
MAO Beyond the Brain
Monoamine oxidase isn’t just a brain enzyme. It’s found throughout the body, including the gut, liver, lungs, and fat tissue. Emerging research is revealing roles for MAO that go well beyond neurotransmitter regulation. In adipose (fat) tissue, for instance, MAO activity appears to be involved in glucose handling and insulin sensitivity. Research in obese animal models has found increased MAO activity in fat cells alongside insulin resistance, suggesting the enzyme participates in metabolic dysfunction.23PubMed Central. Increased monoamine oxidase activity and imidazoline binding sites in insulin-resistant adipocytes from obese Zucker rats In mouse studies, deleting MAO-A specifically from immune cells in fat tissue made glucose intolerance and insulin resistance worse in both males and females, suggesting the enzyme plays a protective role in metabolic health that researchers are only beginning to understand.24The Journal of Nutritional Biochemistry. Myeloid monoamine oxidase A protects against glucose intolerance, insulin resistance and weight gain in high-fat diet-fed mice by preventing the hyperactivation of macrophages
In the brain, MAO-B is drawing attention for a different reason. Reactive astrocytes, a type of support cell that becomes overactive in neurodegenerative disease, use MAO-B to produce hydrogen peroxide, a reactive molecule that can damage neurons. In Alzheimer’s disease models, this MAO-B-generated hydrogen peroxide has been linked to brain inflammation, tau pathology, neuronal death, and cognitive decline.25Nature Neuroscience. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2 production This research is preclinical, but it raises the intriguing possibility that MAO-B inhibitors, already approved for Parkinson’s, could eventually have a role in slowing Alzheimer’s progression. Clinical trials exploring this idea are underway, though none have yet produced definitive results.
Designing Better MAO Inhibitors
The structural differences between MAO-A and MAO-B have become a playground for drug designers. MAO-A’s single binding cavity of roughly 550 cubic angstroms and MAO-B’s two-chambered cavity with a total volume closer to 700 cubic angstroms offer distinct architectural targets.26PubMed Central. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B The molecular gate in MAO-B, formed by a single amino acid residue, can open to merge the two chambers into one larger space when certain inhibitors bind, a feature that makes the enzyme’s behavior more flexible and complex than researchers initially expected.27PubMed. Structural properties of human monoamine oxidases A and B
The goal now is to design molecules that fit precisely into one form’s cavity while ignoring the other, maximizing therapeutic benefit while minimizing side effects. Researchers have identified specific amino acid positions that determine whether an inhibitor will prefer MAO-A or MAO-B, and swapping a single amino acid at one of these positions can flip an enzyme’s selectivity entirely.28PubMed. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid This kind of precision matters because the ideal drug for depression would hit MAO-A in the brain without touching MAO-A in the gut (avoiding tyramine problems) and without hitting MAO-B (avoiding unnecessary side effects). The transdermal selegiline patch accomplished something like this through delivery route rather than molecular design, but a truly brain-selective MAO-A inhibitor taken by mouth remains an elusive target that structural biology might eventually make possible.